Wells Fargo’s Redhill Biopharma RDHL Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q3
Sell
-1
Closed -$9 7042
2024
Q2
$9 Hold
1
﹤0.01% 6645
2024
Q1
$12 Hold
1
﹤0.01% 7253
2023
Q4
$34 Hold
1
﹤0.01% 7039
2023
Q3
$12 Hold
1
﹤0.01% 7352
2023
Q2
$28 Sell
1
-1
-50% -$58 ﹤0.01% 7214
2023
Q1
$196 Hold
2
﹤0.01% 6776
2022
Q4
$272 Hold
2
﹤0.01% 6538
2022
Q3
$1K Hold
2
﹤0.01% 6439
2022
Q2
$2K Buy
2
+1
+100% +$1.37K ﹤0.01% 6361
2022
Q1
$2K Sell
1
-2
-67% -$4.74K ﹤0.01% 6692
2021
Q4
$7K Sell
3
-281
-99% -$1.12M ﹤0.01% 6642
2021
Q3
$1.3M Buy
284
+26
+10% +$176K ﹤0.01% 4027
2021
Q2
$1.78M Buy
258
+58
+29% +$400K ﹤0.01% 3785
2021
Q1
$1.47M Buy
200
+65
+48% +$545K ﹤0.01% 3973
2020
Q4
$1.09M Sell
135
-2
-1% -$18K ﹤0.01% 3967
2020
Q3
$1.4M Buy
137
+136
+13,600% +$1.12M ﹤0.01% 3605
2020
Q2
$9K Hold
1
﹤0.01% 5869
2020
Q1
$4K Hold
1
﹤0.01% 5903
2019
Q4
$5K Sell
1
-1
-50% -$6.39K ﹤0.01% 6043
2019
Q3
$17K Buy
2
+1
+100% +$7.28K ﹤0.01% 5843
2019
Q2
$6K Hold
1
﹤0.01% 6010
2019
Q1
$7K Hold
1
﹤0.01% 5688
2018
Q4
$5K Hold
1
﹤0.01% 6077
2018
Q3
$8K Hold
1
﹤0.01% 6042
2018
Q2
$8K Hold
1
﹤0.01% 6007
2018
Q1
$3K Hold
1
﹤0.01% 6149
2017
Q4
$3K Sell
1
-2
-67% -$13.5K ﹤0.01% 6146
2017
Q3
$35K Hold
3
﹤0.01% 5571
2017
Q2
$24K Hold
3
﹤0.01% 5593
2017
Q1
$27K Buy
3
+1
+50% +$9.99K ﹤0.01% 5640
2016
Q4
$21K Hold
2
﹤0.01% 5614
2016
Q3
$27K Sell
2
-1
-33% -$14K ﹤0.01% 5514
2016
Q2
$33K Sell
3
-1
-25% -$11.6K ﹤0.01% 5339
2016
Q1
$49K Hold
4
﹤0.01% 5227
2015
Q4
$52K Hold
4
﹤0.01% 5262
2015
Q3
$52K Buy
4
+1
+33% +$14.8K ﹤0.01% 5251
2015
Q2
$53K Hold
3
﹤0.01% 5308
2015
Q1
$44K Hold
3
﹤0.01% 5069
2014
Q4
$40K Hold
3
﹤0.01% 5099
2014
Q3
$40K Hold
3
﹤0.01% 5018
2014
Q2
$52K Hold
3
﹤0.01% 4962
2014
Q1
$42K Buy
+3
New +$40.2K ﹤0.01% 4980

Other funds holding RDHL

Wells Fargo's RDHL Position: Q3 2024 in Review

Wells Fargo sold out of Redhill Biopharma (RDHL) in Q3 2024, closing a stake of 1 share — an estimated $9 sold.

Wells Fargo first reported a position in RDHL in Q1 2014 and held it in 42 quarters. The position peaked at $1.78M in Q2 2021. 11 funds tracked by Wall St. Rank hold RDHL as of Q3 2024.

  • Wells Fargo reported no remaining Redhill Biopharma position as of Q3 2024 after selling out during the quarter.
  • Wells Fargo sold 1 Redhill Biopharma share in Q3 2024, an estimated $9.
  • Wells Fargo first reported a position in Redhill Biopharma in Q1 2014 and held it in 42 quarters.
  • Wells Fargo's Redhill Biopharma position peaked at $1.78M in Q2 2021.
  • 11 funds tracked by Wall St. Rank held Redhill Biopharma as of Q3 2024.

Based on Wells Fargo's 13F filing for Q3 2024, filed 13 Nov 2024.